Peter W Chung

List of Publications by Year
in descending order

167 papers	5,840 citations	76326 40 h-index	85541 71 g-index
171 all docs	171 docs citations	171 times ranked	6047 citing authors

#	Article	IF	Citations
1	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1884-1890.	1.6	521
2	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. Journal of Clinical Oncology, 2015, 33, 51-57.	1.6	268
3	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1366-1377.	10.7	266
4	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology, 2017, 35, 2299-2305.	1.6	241
5	Dynamic Contrast-Enhanced Magnetic Resonance Imaging forÂLocalization of Recurrent Prostate Cancer After ExternalÂBeam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 425-430.	0.8	234
6	Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 2108-2114.	7.0	233
7	Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. Journal of Clinical Oncology, 2018, 36, 704-709.	1.6	155
8	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1084-1089.	0.8	139
9	The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer, 2014, 120, 2866-2875.	4.1	139
10	Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Medicine, 2015, 4, 155-160.	2.8	129
11	Canadian consensus guidelines for the management of testicular germ cell cancer. Canadian Urological Association Journal, 2013, 4, 19.	0.6	119
12	Stage II Testicular Seminoma: Patterns of Recurrence and Outcome of Treatment. European Urology, 2004, 45, 754-760.	1.9	115
13	Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. Cancer Research, 2007, 67, 6022-6025.	0.9	109
14	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. Journal of Urology, 2018, 200, 126-135.	0.4	107
15	Local recurrence of localized soft tissue sarcoma. Cancer, 2012, 118, 5867-5877.	4.1	100
16	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 303-309.	1.6	98
17	Changes in apparent diffusion coefficient and T₂ relaxation during radiotherapy for prostate cancer. Journal of Magnetic Resonance Imaging, 2013, 37, 909-916.	3.4	74
18	Evidence-based guidelines for following stage 1 seminoma. Cancer, 2007, 109, 2248-2256.	4.1	73

#	Article	IF	Citations
19	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer, 2019, 125, 1290-1300.	4.1	71
20	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Optionsâ€"An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 2016, 34, 345-351.	1.6	69
21	The clinical and functional outcome for patients with radiationâ€induced soft tissue sarcoma. Cancer, 2012, 118, 2682-2692.	4.1	67
22	Spermatocytic Seminoma: A Review. European Urology, 2004, 45, 495-498.	1.9	66
23	Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey. Supportive Care in Cancer, 2012, 20, 2737-2746.	2.2	65
24	Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2021, 11, 339-351.	2.1	65
25	Soft tissue sarcoma presenting with metastatic disease. Cancer, 2011, 117, 372-379.	4.1	64
26	STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.. Journal of Clinical Oncology, 2019, 37, 11001-11001.	1.6	64
27	Image guided dose escalated prostate radiotherapy: still room to improve. Radiation Oncology, 2009, 4, 50.	2.7	57
28	The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma. European Journal of Cancer, 2020, 125, 130-141.	2.8	57
29	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Journal, 2016, 10, 46.	0.6	55
30	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. European Urology, 2017, 71, 120-127.	1.9	54
31	Patient-Assessed Late Toxicity Rates and Principal Component Analysis After Image-Guided Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 690-698.	0.8	53
32	Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e441-e448.	0.8	52
33	Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association Journal, 2018, 13, 230-238.	0.6	51
34	The relationship between external beam radiotherapy dose and chronic urinary dysfunction â€" A methodological critique. Radiotherapy and Oncology, 2010, 97, 40-47.	0.6	49
35	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	1.9	49
36	A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy. Radiotherapy and Oncology, 2005, 76, 11-17.	0.6	47

#	Article	IF	Citations
37	Adverse Effect of Older Age on the Recurrence of Soft Tissue Sarcoma of the Extremities and Trunk. Journal of Clinical Oncology, 2011, 29, 4029-4035.	1.6	47
38	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. Journal of Clinical Oncology, 2019, 37, 1919-1926.	1.6	47
39	Highâ€risk extracranial chondrosarcoma. Cancer, 2011, 117, 2513-2519.	4.1	42
40	Survival outcomes for cutaneous angiosarcoma of the scalp versus face. Head and Neck, 2017, 39, 1205-1211.	2.0	42
41	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 546-555.	0.8	42
42	Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. European Radiology, 2010, 20, 1624-1630.	4.5	41
43	Treatment burden in stage <scp>I</scp> seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU International, 2013, 112, 1088-1095.	2.5	40
44	MR-guided Prostate Biopsy for Planning of Focal Salvage after Radiation Therapy. Radiology, 2015, 274, 181-191.	7.3	40
45	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. European Urology Oncology, 2021, 4, 483-491.	5.4	39
46	Stage I Seminoma: Adjuvant Treatment is Effective but is it Necessary?. Journal of the National Cancer Institute, 2011, 103, 194-196.	6.3	38
47	Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma. Journal of Surgical Oncology, 2019, 119, 856-863.	1.7	37
48	No Role for Routine Chest Radiography in Stage I Seminoma Surveillance. European Urology, 2010, 57, 474-479.	1.9	33
49	Utility of serum tumor markers during surveillance for stage I seminoma. Cancer, 2012, 118, 5245-5250.	4.1	33
50	Patient-specific PTV margins in radiotherapy for bladder cancer â€“ A feasibility study using cone beam CT. Radiotherapy and Oncology, 2011, 99, 131-136.	0.6	31
51	Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses. Radiotherapy and Oncology, 2009, 90, 325-330.	0.6	30
52	Clinical Application of High-Dose, Image-Guided Intensity-Modulated Radiotherapy in High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 477-483.	0.8	29
53	Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 328-334.	1.6	29
54	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2016, 15, 147-155.	0.5	28

#	Article	IF	Citations
55	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. European Urology Focus, 2018, 4, 995-1001.	3.1	26
56	A randomized comparison of interfraction and intrafraction prostate motion with and without abdominal compression. Radiotherapy and Oncology, 2008, 88, 88-94.	0.6	25
57	Role of Principal Component Analysis in Predicting Toxicity in Prostate Cancer Patients Treated With Hypofractionated Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e415-e421.	0.8	25
58	Radiation therapy in retroperitoneal sarcoma management. Journal of Surgical Oncology, 2018, 117, 93-98.	1.7	25
59	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology, 2015, 5, e473-e482.	2.1	24
60	A Device and Procedure for Immobilization of Patients Receiving Limb-Preserving Radiotherapy for Soft Tissue Sarcoma. Medical Dosimetry, 2009, 34, 243-249.	0.9	23
61	The effect of delineation method and observer variability on bladder dose-volume histograms for prostate intensity modulated radiotherapy. Radiotherapy and Oncology, 2011, 101, 479-485.	0.6	23
62	Readout-segmented echo-planar diffusion-weighted imaging improves geometric performance for image-guided radiation therapy of pelvic tumors. Radiotherapy and Oncology, 2015, 117, 525-531.	0.6	23
63	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. Journal of Urology, 2015, 194, 386-391.	0.4	23
64	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology, 2017, 122, 93-98.	0.6	23
65	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. Journal of Urology, 2018, 200, 283-291.	0.4	22
66	Surveillance in stage I testicular seminoma. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 75-79.	1.6	21
67	An Analysis of Tumor- and Surgery-Related Factors that Contribute to Inadvertent Positive Margins Following Soft Tissue Sarcoma Resection. Annals of Surgical Oncology, 2017, 24, 2137-2144.	1.5	21
68	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	21
69	Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature. Oncology and Therapy, 2021, 9, 21-39.	2.6	20
70	Spatial and volumetric changes of retroperitoneal sarcomas during pre-operative radiotherapy. Radiotherapy and Oncology, 2014, 112, 308-313.	0.6	19
71	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology, 2017, 123, 459-465.	0.6	18
72	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. Journal of Urology, 2019, 201, 284-291.	0.4	18

#	Article	IF	Citations
73	Inter-professional variability in the assignment and recording of acute toxicity grade using the RTOG system during prostate radiotherapy. Radiotherapy and Oncology, 2009, 90, 395-399.	0.6	17
74	The value of adaptive preoperative radiotherapy in management of soft tissue sarcoma. Radiotherapy and Oncology, 2017, 122, 458-463.	0.6	17
75	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.6	17
76	Health-related quality of life following treatment for extremity soft tissue sarcoma. Journal of Surgical Oncology, 2016, 114, 821-827.	1.7	16
77	Evaluation of high dose volumetric CT to reduce inter-observer delineation variability and PTV margins for prostate cancer radiotherapy. Radiotherapy and Oncology, 2017, 125, 118-123.	0.6	16
78	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. Current Oncology Reports, 2020, 22, 14.	4.0	16
79	Outcome following radiotherapy for head and neck basal cell carcinoma with â€˜aggressiveâ€™ features. Oral Oncology, 2017, 72, 157-164.	1.5	15
80	PMH 9907: Longâ€term outcomes of a randomized phase 3 study of shortâ€term bicalutamide hormone therapy and doseâ€escalated externalâ€beam radiation therapy for localized prostate cancer. Cancer, 2016, 122, 2595-2603.	4.1	14
81	Changes in apparent diffusion coefficient radiomics features during dose-painted radiotherapy and high dose rate brachytherapy for prostate cancer. Physics and Imaging in Radiation Oncology, 2019, 9, 1-6.	2.9	14
82	Comparison of 3 image-guided adaptive strategies for bladder locoregional radiotherapy. Medical Dosimetry, 2019, 44, 111-116.	0.9	14
83	Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma. Annals of Surgical Oncology, 2020, 27, 2033-2041.	1.5	14
84	Contemporary Management of Stage I and II Seminoma. Current Urology Reports, 2013, 14, 525-533.	2.2	13
85	Treatment-related toxicity and symptom-related bother followingpostoperative radiotherapy for prostate cancer. Canadian Urological Association Journal, 2013, 4, 105.	0.6	13
86	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. Clinical Genitourinary Cancer, 2018, 16, e193-e199.	1.9	13
87	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. European Urology Oncology, 2021, 4, 289-296.	5.4	13
88	Clinical prostate T₂ quantification using magnetizationâ€prepared spiral imaging. Magnetic Resonance in Medicine, 2010, 64, 1155-1161.	3.0	12
89	Prostate radiotherapy clinical trial quality assurance: How real should real time review be? (A) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	12
90	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. Canadian Urological Association Journal, 2017, 12, 59-66.	0.6	12

#	Article	IF	Citations
91	Primary Tracheal Ewing's Sarcoma. Annals of Thoracic Surgery, 2010, 90, 1349-1352.	1.3	11
92	Radiation Therapy for Infiltrative Giant Cell Tumor of the Tendon Sheath. Journal of Hand Surgery, 2012, 37, 775-782.	1.6	11
93	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. European Urology Oncology, 2019, 2, 437-442.	5.4	11
94	Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 608-616.	0.8	10
95	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Canadian Urological Association Journal, 2016, 10, 204.	0.6	10
96	Technical Note: Method to correlate whole-specimen histopathology of radical prostatectomy with diagnostic MR imaging. Medical Physics, 2016, 43, 1065-1072.	3.0	10
97	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiotherapy and Oncology, 2020, 149, 240-245.	0.6	10
98	Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. Cureus, 2017, 9, e1764.	0.5	10
99	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology, 2021, 28, 107-114.	2.2	10
100	Treatment Options, Prognostic Factors and Selection of Treatment in Stage I Seminoma. Oncology Research and Treatment, 2006, 29, 592-598.	1.2	9
101	Axial Skeletal Location Predicts Poor Outcome in Ewing's Sarcoma: A Single Institution Experience. Sarcoma, 2011, 2011, 1-5.	1.3	9
102	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2018, 12, E281-97.	0.6	9
103	Planned versus â€˜deliveredâ€™ bladder dose reconstructed using solid and hollow organ models during prostate cancer IMRT. Radiotherapy and Oncology, 2016, 119, 417-422.	0.6	8
104	MR elastography to measure the effects of cancer and pathology fixation on prostate biomechanics, and comparison withT₁,T₂and ADC. Physics in Medicine and Biology, 2017, 62, 1126-1148.	3.0	8
105	Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. Radiotherapy and Oncology, 2017, 122, 103-108.	0.6	8
106	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. BJU International, 2018, 122, 814-822.	2.5	8
107	[¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	1.9	8
108	Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. Practical Radiation Oncology, 2014, 4, 323-329.	2.1	7

#	Article	IF	Citations
109	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiation Oncology, 2017, 12, 50.	2.7	7
110	Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life. Brachytherapy, 2019, 18, 477-483.	0.5	7
111	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. European Urology Oncology, 2019, 2, 88-96.	5.4	7
112	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	1.2	7
113	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clinical and Translational Radiation Oncology, 2022, 32, 41-47.	1.7	7
114	The Effect of Registration Surrogate and Patient Factors on the Interobserver Variability of Electronic Portal Image Guidance During Prostate Radiotherapy. Medical Dosimetry, 2011, 36, 337-343.	0.9	6
115	Prostate T₁ quantification using a magnetizationâ€prepared spiral technique. Journal of Magnetic Resonance Imaging, 2011, 33, 474-481.	3.4	6
116	Dosimetric impact of intrafraction changes in MR-guided high-dose-rate (HDR) brachytherapy for prostate cancer. Brachytherapy, 2018, 17, 59-67.	0.5	6
117	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association Journal, 2016, 10, 90.	0.6	6
118	Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. European Urology Open Science, 2022, 40, 46-53.	0.4	6
119	In regard to RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume and Clinical Target Volume on Computed Tomographic Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in Radiation Therapy Oncology Group Studies: In regard to Wang etÂal (Int J Radiat Oncol Biol Phys 2011;81:e525â€“e528). International Journal of Radiation Oncology Biology Physics, 2012, 83, 433.	0.8	5
120	Impact of image registration surrogates on the planning target volume geometry for bladder radiation therapy. Practical Radiation Oncology, 2016, 6, e187-e194.	2.1	5
121	Testicular cancer: seminoma. Clinical Evidence, 2011, 2011, .	0.2	5
122	Automated Delineation of the Normal Urinary Bladder on Planning CT andÂCone Beam CT. Journal of Medical Imaging and Radiation Sciences, 2016, 47, 21-29.	0.3	4
123	Assessment of intravascular granulomas in testicular seminomas and their association with tumour relapse and dissemination. Journal of Clinical Pathology, 2016, 69, 47-52.	2.0	4
124	Evaluation of resource burden for bladder adaptive strategies: A timing study. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 861-865.	1.8	4
125	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. Canadian Urological Association Journal, 2020, 14, E588-E593.	0.6	4
126	Controversies in the management of clinical stage 1 testis cancer. Canadian Urological Association Journal, 2020, 14, E537-E542.	0.6	4

#	Article	IF	Citations
127	Coronavirus Disease 2019â€™s (COVID-19â€™s) Silver Liningâ€"Through the Eyes of Radiation Oncology Fellows. Advances in Radiation Oncology, 2021, 6, 100527.	1.2	4
128	Magnetic Resonance Imaging-guided Brachytherapy Re-irradiation for Isolated Local Recurrence of Soft Tissue Sarcoma. Cureus, 2018, 10, e2457.	0.5	4
129	Retroperitoneal hematoma following radical orchiectomy: Two cases. Canadian Urological Association Journal, 2017, 11, 35.	0.6	3
130	Testicular seminoma: Scattered radiation dose to the contralateral testis in the modern era. Practical Radiation Oncology, 2018, 8, e57-e62.	2.1	3
131	Efficient and Effective Personalization of PTV Margins During Radiation Therapy for Bladder Cancer. Journal of Medical Imaging and Radiation Sciences, 2018, 49, 420-427.	0.3	3
132	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.6	3
133	Quantification of interobserver variability in image registration using cone beam CT for partial bladder radiotherapyâ€"a comparison between lipiodol and bladder wall surface. British Journal of Radiology, 2019, 92, 20180413.	2.2	3
134	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. Urology, 2020, 138, 69-76.	1.0	3
135	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e1-848.e7.	1.6	3
136	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2020, 14, 404-410.	0.6	3
137	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.6	3
138	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 835.e1-835.e7.	1.6	3
139	Testicular cancer: germ cell tumours. Clinical Evidence, 2016, 2016, .	0.2	3
140	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.6	3
141	Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma. Annals of Surgical Oncology, 2022, 29, 2304.	1.5	3
142	Salvage MRI-Guided and Tumor-Targeted HDR Prostate Brachytherapy after External Beam Radiotherapy. Brachytherapy, 2014, 13, S38-S39.	0.5	2
143	Delineating the inner bladder surface using uniform contractions from the outer surface under variable bladder filling conditions. British Journal of Radiology, 2015, 88, 20140818.	2.2	2
144	Evidence-based region of interest matching guidelines for sarcoma volumetric image-guided radiation therapy. Technical Innovations and Patient Support in Radiation Oncology, 2018, 5, 3-8.	1.9	2

#	Article	IF	Citations
145	Impact of high dose volumetric CT on PTV margin reduction in VMAT prostate radiotherapy. Physics in Medicine and Biology, 2019, 64, 065017.	3.0	2
146	Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2021, 23, 36.	4.0	2
147	Case series illustrating the synergistic use of hydrogel spacer and MR-guidance to increase the radiotherapeutic index for localized prostate cancer. Technical Innovations and Patient Support in Radiation Oncology, 2019, 11, 22-25.	1.9	2
148	TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification. European Urology, 2022, 82, e52-e53.	1.9	2
149	Tumour-Targeted Treatment Intensification for Prostate Cancer Using Magnetic Resonance Imaging Guidance. Journal of Medical Imaging and Radiation Sciences, 2017, 48, 336-342.	0.3	1
150	Use of hydrogel spacer for improved rectal dose-sparing in patients undergoing radical radiotherapy for localized prostate cancer: First Canadian experience. Canadian Urological Association Journal, 2017, 11, 373-5.	0.6	1
151	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 702-709.	0.8	1
152	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. European Urology Open Science, 2020, 21, 1-4.	0.4	1
153	Clinical dilemmas in local and regional testis cancer. Canadian Urological Association Journal, 2020, 15, E58-E64.	0.6	1
154	Current Management of Localized Muscle-Invasive Bladder Cancer: AÂConsensus Guideline from the Genitourinary Medical Oncologists ofÂCanada. Bladder Cancer, 2020, 6, 363-392.	0.4	1
155	Prostate or bone? Comparing the efficacy of image guidance surrogates for pelvis and prostate radiotherapy using accumulated delivered dose. Journal of Medical Imaging and Radiation Sciences, 2021, 52, 14-21.	0.3	1
156	Soft Tissue Sarcoma. , 2012, , 1355-1391.		1
157	Radiological progression of extremity soft tissue sarcoma following pre-operative radiotherapy predicts for poor survival. British Journal of Radiology, 2022, 95, 20210936.	2.2	1
158	Reply to monitoring of seminoma patients with serum markers. Cancer, 2013, 119, 2511-2512.	4.1	0
159	Regional Therapy Might Have a Role. International Journal of Radiation Oncology Biology Physics, 2017, 99, 511.	0.8	0
160	Stereotactic ablative radiotherapy with targeted MRI-defined gross tumor dose escalation for prostate cancer: dosimetric feasibility and interfraction robustness. Journal of Radiation Oncology, 2017, 6, 397-404.	0.7	0
161	Reply to A. Levy et al. Journal of Clinical Oncology, 2018, 36, 2358-2359.	1.6	0
162	A Canadian approach to the regionalization of testis cancer: A review. Canadian Urological Association Journal, 2020, 14, 346-351.	0.6	0

#	Article	IF	Citations
163	Trimodal Therapy. , 2021, , 257-280.		0
164	ASO Visual Abstract: The Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma (RPS). Annals of Surgical Oncology, 2022, 29, 2315.	1.5	0
165	Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy. Technical Innovations and Patient Support in Radiation Oncology, 2022, 21, 64-70.	1.9	0
166	The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
167	Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver. Frontiers in Oncology, 2022, 12, 877452.	2.8	0